Latest Algeta ASA (ALGZF) Headlines Bayer AG
Post# of 5
Posted On: 03/08/2014 6:32:16 PM
Latest Algeta ASA (ALGZF) Headlines
Bayer AG (ADR) Gets Regulatory Approval For Purchase of Algeta
Eileen Rojas, The Motley Fool - Motley Fool - Fri Jan 10, 10:30AM CST
German pharmaceutical company Bayer AG may soon have a new prostate cancer therapy called Xofigo in its drug pipeline. The Federal Cartel Office, Germany's antitrust authority, approved Bayer's purchase of the drug's co-creator , Norwegian biotech...
Immunomedics in Collaboration With Algeta to Evaluate Potential of Epratuzumab Conjugated to Alpha-Emitter Thorium-227
GlobeNewswire - Mon Jan 28, 6:00AM CST
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced an agreement with Algeta ASA (OSE:ALGETA) for the development of Immunomedics' humanized anti-CD22 antibody, epratuzumab, conjugated with Algeta's proprietary thorium-227 alpha-pharmaceutical payload.
Algeta initiates new oncology research program to evaluate the potential of a Targeted Thorium Conjugate (TTC) based on Immunomedics' anti-CD22 monoclonal antibody
Marketwire - Mon Jan 28, 12:21AM CST
CD22 is a well-validated target for hematological cancers
US Nuclear Regulatory Commission issues a licensing decision under 10 CFR Part 35 Subpart E for radium-223 dichloride
Thomson Reuters ONE - Mon Jan 14, 12:02AM CST
Not Intended for US Media
Bayer AG (ADR) Gets Regulatory Approval For Purchase of Algeta
Eileen Rojas, The Motley Fool - Motley Fool - Fri Jan 10, 10:30AM CST
German pharmaceutical company Bayer AG may soon have a new prostate cancer therapy called Xofigo in its drug pipeline. The Federal Cartel Office, Germany's antitrust authority, approved Bayer's purchase of the drug's co-creator , Norwegian biotech...
Immunomedics in Collaboration With Algeta to Evaluate Potential of Epratuzumab Conjugated to Alpha-Emitter Thorium-227
GlobeNewswire - Mon Jan 28, 6:00AM CST
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced an agreement with Algeta ASA (OSE:ALGETA) for the development of Immunomedics' humanized anti-CD22 antibody, epratuzumab, conjugated with Algeta's proprietary thorium-227 alpha-pharmaceutical payload.
Algeta initiates new oncology research program to evaluate the potential of a Targeted Thorium Conjugate (TTC) based on Immunomedics' anti-CD22 monoclonal antibody
Marketwire - Mon Jan 28, 12:21AM CST
CD22 is a well-validated target for hematological cancers
US Nuclear Regulatory Commission issues a licensing decision under 10 CFR Part 35 Subpart E for radium-223 dichloride
Thomson Reuters ONE - Mon Jan 14, 12:02AM CST
Not Intended for US Media
(0)
(0)